Last reviewed · How we verify
Tislelizumab，atezolizumab or sugemalimab
Tislelizumab，atezolizumab or sugemalimab is a Small molecule drug developed by Base Therapeutics (Shanghai) Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Tislelizumab，atezolizumab or sugemalimab |
|---|---|
| Sponsor | Base Therapeutics (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of NK510 to Treat NSCLC (EARLY_PHASE1)
- Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial (PHASE1, PHASE2)
- Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
- Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tislelizumab，atezolizumab or sugemalimab CI brief — competitive landscape report
- Tislelizumab，atezolizumab or sugemalimab updates RSS · CI watch RSS
- Base Therapeutics (Shanghai) Co., Ltd. portfolio CI
Frequently asked questions about Tislelizumab，atezolizumab or sugemalimab
What is Tislelizumab，atezolizumab or sugemalimab?
Tislelizumab，atezolizumab or sugemalimab is a Small molecule drug developed by Base Therapeutics (Shanghai) Co., Ltd..
Who makes Tislelizumab，atezolizumab or sugemalimab?
Tislelizumab，atezolizumab or sugemalimab is developed by Base Therapeutics (Shanghai) Co., Ltd. (see full Base Therapeutics (Shanghai) Co., Ltd. pipeline at /company/base-therapeutics-shanghai-co-ltd).
What development phase is Tislelizumab，atezolizumab or sugemalimab in?
Tislelizumab，atezolizumab or sugemalimab is in Phase 1.